cd30.car-ebvst
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2020 (NCT04288726)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor necrosis factor receptor superfamily member 8Immunity, passive
immunity, passive - CD30
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06176690 | Phase 1 | Jun 1, 2024 | Baylor University, The University of Texas, Dallas |
| NCT04952584 | Phase 1 | Sep 30, 2021 | Baylor University, The University of Texas, Dallas |
| NCT04288726 | Phase 1 | Jun 1, 2020 | Baylor University, Methodist Cancer Center, Houston, Texas |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 3 | 3 | 1 | 2020 |
| The University of Texas, Dallas | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1